| Previous Close | 2.29 |
| Open | 2.31 |
| Volume | 36,713 |
| Avg. Volume (3M) | 560,063 |
| Market Cap | 177,202,864 |
| Price / Sales | 25.39 |
| Price / Book | 1.62 |
| 52 Weeks Range | |
| Earnings Date | 26 Aug 2025 - 1 Sep 2025 |
| Diluted EPS (TTM) | -0.550 |
| Total Debt/Equity (MRQ) | 1.86% |
| Current Ratio (MRQ) | 22.35 |
| Operating Cash Flow (TTM) | -52.67 M |
| Levered Free Cash Flow (TTM) | -68.15 M |
| Return on Assets (TTM) | -11.05% |
| Return on Equity (TTM) | -19.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | I-MAB | Bullish | Bearish |
AIStockmoo Score
1.1
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 0.5 |
| Average | 1.13 |
|
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 10.80% |
| % Held by Institutions | 29.64% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Edbi Pte Ltd | 31 Dec 2024 | 222,136 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 7.00 (HC Wainwright & Co., 222.58%) | Buy |
| 7.00 (BTIG, 222.58%) | Buy | |
| Median | 7.00 (222.58%) | |
| Low | 6.00 (Needham, 176.50%) | Buy |
| Average | 6.67 (207.37%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 4.39 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 10 Sep 2025 | 7.00 (222.58%) | Buy | 4.18 |
| 09 Sep 2025 | 7.00 (222.58%) | Buy | 4.60 | |
| Needham | 08 Sep 2025 | 6.00 (176.50%) | Buy | 4.27 |
| 20 Aug 2025 | 6.00 (176.50%) | Buy | 4.52 | |
| HC Wainwright & Co. | 21 Aug 2025 | 7.00 (222.58%) | Buy | 4.71 |
| 09 Jul 2025 | 7.00 (222.58%) | Buy | 2.31 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |